Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

• Hauptverfasser: Shinya Tsuboi (Verfasst von), Tatsuya Hayama (Verfasst von), Katsuhiro Miura (Verfasst von), Akihiro Uchiike (Verfasst von), Daisuke Tsutsumi (Verfasst von), Takashi Yamauchi (Verfasst von), Yoshihiro Hatta (Verfasst von), Susumu Ootsuka (Verfasst von)
• Format: Buch
• Veröffentlicht: BMC, 2023-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant adverse event occurring during cancer treatment. Thus, we aim...